[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.
B Coudert, T Ciuleanu, K Park, YL Wu… - Annals of Oncology …, 2011 - europepmc.org
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
B Coudert, T Ciuleanu, K Park, YL Wu… - ANNALS OF …, 2012 - scholarworks.bwise.kr
Background: In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
B Coudert, T Ciuleanu, K Park… - Annals of oncology …, 2012 - pubmed.ncbi.nlm.nih.gov
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
B Coudert, T Ciuleanu, K Park, YL Wu… - Annals of …, 2012 - annalsofoncology.org
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
[引用][C] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
B COUDERT, T CIULEANU, K PARK… - Annals of …, 2012 - pascal-francis.inist.fr
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell
lung cancer (NSCLC) according to response to first-line chemotherapy CNRS Inist Pascal-Francis …
lung cancer (NSCLC) according to response to first-line chemotherapy CNRS Inist Pascal-Francis …
[引用][C] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
B Coudert, T Ciuleanu, K Park, YL Wu, G Giaccone… - Annals of …, 2012 - cir.nii.ac.jp
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell
lung cancer (NSCLC) according to response to first-line chemotherapy | CiNii Research CiNii …
lung cancer (NSCLC) according to response to first-line chemotherapy | CiNii Research CiNii …
[PDF][PDF] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
B Coudert, T Ciuleanu, K Park, YL Wu, G Giaccone… - 2011 - researchgate.net
Background: In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
B Coudert, T Ciuleanu, K Park… - Annals of …, 2012 - mdanderson.elsevierpure.com
Background: In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
[PDF][PDF] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
B Coudert, T Ciuleanu, K Park, YL Wu, G Giaccone… - 2011 - gdghospital.org.cn
Background: In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …